Showing 1,381 - 1,400 results of 101,575 for search '(( 50 ms decrease ) OR ( 5 ((wt decrease) OR (((mean decrease) OR (a decrease)))) ))', query time: 1.31s Refine Results
  1. 1381
  2. 1382
  3. 1383

    Increase of proliferating progenitor cells and decrease of terminally differentiated granule neurons in the immature dentate gyrus of <i>PC3/Tis21</i>-null mice at P14. by Stefano Farioli-Vecchioli (256006)

    Published 2009
    “…(<b>B</b>, <b>C</b>) The same significant increase is observed for the number of dividing progenitor cells, identified either as (<b>B</b>) Ki67-positive, or as (<b>C</b>) Ki67/Sox2-positive cells (1.5-fold). (<b>D</b>) The newly generated neurons (1 hour pulse of BrdU) decreased sharply (20%). …”
  4. 1384
  5. 1385
  6. 1386

    List of Included studies. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  7. 1387

    The search strategy in three databases. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  8. 1388

    NIH score. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  9. 1389

    List of excluded studies. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  10. 1390
  11. 1391
  12. 1392

    Nilotinib decreases HEI-193 cell viability in a time-, dose-, and growth condition- dependent manner. by Nesrin Sabha (127278)

    Published 2013
    “…(B) HEI-193 grown in PDGF media were treated with 0, 3, 5, 10 or 20 µM nilotinib up to 5 days. Trypan blue viability assay shows decreased number of viable cells at 5 days in 3 µM nilotinib, compared to vehicle shown, mean and SD of six technical replicates. …”
  13. 1393
  14. 1394
  15. 1395
  16. 1396
  17. 1397

    Decreased dermal and corneal stromal collagen in <i>Slc39a13</i>-KO mice. by Toshiyuki Fukada (156297)

    Published 2008
    “…Data represent mean±S.D. F. Collagen of corneal stroma is decreased in <i>Slc39a13</i>-KO mice. …”
  18. 1398
  19. 1399
  20. 1400

    Blocking TNF or IL-6 decreases HIV-1 replication significantly in a dose dependent manner. by Shahin Ranjbar (66979)

    Published 2013
    “…Blocking TNF (at 2 ug/ml or 5 ug/ml) or IL-6 (5 ug/ml) significantly decreased virus replication (*, p<0.05) as compared to the same concentrations of an IgG<sub>1</sub> control antibody. …”